Altria Group Trading Volume Plummets 54.72 Percent to 343rd Position as FDA Authorizes Juul Labs E-Cigarette Sales

On July 18, 2025, Altria Group (MO) saw a significant drop in trading volume, with a total of $329 million in shares traded, marking a 54.72% decrease from the previous day. This placed Altria at the 343rd position in terms of trading volume for the day.

The U.S. Food and Drug Administration (FDA) has authorized the sale of Juul Labs' e-cigarette device and refill cartridges in tobacco and menthol flavors. This decision comes after a lengthy regulatory process and ends a ban that was imposed in 2022. The authorization is expected to stabilize Juul's market position within the $45 billion e-cigarette industry.

Following the FDA's authorization, shares of Altria Group declined. The regulatory shift in favor of Juul Labs has significant implications for the e-cigarette market, potentially impacting Altria's market position and strategic partnerships. The FDA's decision to authorize Juul's products after a yearslong delay is seen as a major regulatory shift, which could influence the competitive landscape in the e-cigarette industry.